Authoring more than 400 articles in medical and scientific journals, Dr. Bréchot was ranked by the Institute for Scientific Information as the 4th most cited author on the topic of hepatitis C. He has been recognized as an inventor on 18 patents, and helped create three biotechnology companies: Rarecells, ALFACT Innovation, and The Healthy Aging Company.
Dr. Bréchot’s research activities have focused on viral hepatitis: hepatitis B (HBV) and C (HCV), particularly with regard to their role in liver cancer (Hepatocellular carcinoma: HCC) and to the molecular mechanisms that drive liver regeneration and cancer (in particular, cell cycle deregulation and the impact of oxydative stress). Additionally, Dr. Bréchot’s research interests also include microbiomes, particularly in the area of microbiomes and viral infections. In this respect, he is a co-founder of the Microbiome, Immunology and Infection Control (MIIM) in the USF Pandemic Response Research Network (PRRN). This research hub focuses on enabling and connecting an interdisciplinary network of scientists at USF and globally. The hub's goals are to develop precision therapies and interventions that target the human microbiome to maintain and restore human health against COVID-19 and future such pandemics. Dr. Bréchot is also head of the USF Initiative on Microbiomes. He has been the member of numerous scientific committees and societies and has received prestigious awards.